Scott M. Rocklage is a Venture Partner in 5AM Ventures. He holds a Ph.D. in chemistry earned at the Massachusetts Institute of Technology where he was responsible for doing research in the laboratory of the Nobel Prize winner for the field of chemistry in 2005, Richard R. Schrock. Additionally Dr. Rocklage has a BS in chemistry from when he attended the University of California in Berkeley. In 2004 Dr. Rocklage became a managing partner for 5AM Ventures. His experience in the health care management field goes back thirty years.
Dr. Rocklage’s responsibilities in strategic leadership led to the approval by the FDA for three new drug applications in the United States. These were Cubicin, Teslascan and Omniscan. Dr. Rocklage was also responsible for six additional drugs being entered as candidates for clinical trials.
Dr. Rocklage has served in numerous esteemed positions including being the CEO and Chairman at Cubist Pharmaceuticals, the CEO and positions in R&D for Nycomed Salutar as well as R&D at Catalytica. Dr. Rocklage has also been in the position of Board Chairman for Novira which later became an acquisition of J&J and Relypsa.
Currently Dr. Scott Rocklage is the Board Chairman for Cidara, Kinestral and Rennovia. In addition to these responsibilities he is on the Boards for Pulmatrix and Epirus. Previously Dr. Rocklage was the Executive Chairman for the company Ilypsa which was later acquired by Amgen. He held the same position for Miikana which was acquired by EntreMed and Sempris which was acquired by Teleflex.
Dr. Rocklage is either the actual inventor or the co-inventor of well over thirty United States patents and has over 100 publications that have been reviewed by his peers. His office is located in Boston, Massachusetts. He has established a long and dignified career.